Organization
Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
3 abstracts
Abstract
Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.Org: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Surgery, Jiangxi Cancer Hospital, Nanchang, China, Hunan Cancer Hospital, Changsha, China, Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China,
Abstract
Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study.Org: Department of Breast, Henan Cancer Hospital, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Department of Medical Oncology, General Hospital of Ningxia Medical University, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Cancer Center, Sun Yat-sen University, Guangzhou, China,
Abstract
A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02.Org: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Affiliated Hospital of Hebei Engineering University, Handan, China, First Hospital of Qinhuangdao, Qinhuangdao, China, Qinhuangdao Maternal and Child Health Hospital, Qinhuangdao, China,